Prolia Pricing: A High Bar For Osteoporosis But Room To Tap Oncology Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
With a wholesale acquisition cost of $1,650 a year for Prolia, Amgen has effectively sacrificed the first-line treatment market for osteoporosis in favor of long-term potential in future indications.